TE_38017
Basic information Differential Expression Stage analysis Survival analysis Correlation analysis| TE family | AluY |
|---|---|
| TE superfamily | Alu |
| TE class | SINE |
| Gene | - |
| Class | Intergenic |
| Coding | Non-coding |
| Tumor-specific score | 170.19 |
| Counts of samples | TCGA_tumor:150; TCGA_normal:0; GTEx:0 |
| TSS | chrX(-):94715418 |
Transcript isoforms
| Transcript_ID | Gene | Class | Coding | ORF | Position |
|---|---|---|---|---|---|
| teRNA_38017.1 | - | Intergenic | Non-coding | Non-coding | chrX(-):94697989,94698009,94715210,94715419 |
| teRNA_38017.2 | - | Intergenic | Non-coding | Non-coding | chrX(-):94692981,94693001,94697896,94698009,94715210,94715419 |
| teRNA_38017.3 | - | Intergenic | Non-coding | Non-coding | chrX(-):94673050,94673070,94697896,94698009,94715210,94715419 |
| teRNA_38017.4 | - | Intergenic | Non-coding | Non-coding | chrX(-):94613280,94613300,94697896,94698009,94715210,94715419 |
| teRNA_38017.5 | - | Intergenic | Non-coding | Non-coding | chrX(-):94697080,94697100,94697896,94698009,94715210,94715419 |
| teRNA_38017.6 | - | Intergenic | Non-coding | Non-coding | chrX(-):94651619,94651639,94697896,94698009,94715210,94715419 |
| teRNA_38017.7 | - | Intergenic | Non-coding | Non-coding | chrX(-):94620415,94620435,94697896,94698009,94715210,94715419 |
| teRNA_38017.8 | - | Intergenic | Non-coding | Non-coding | chrX(-):94683999,94684019,94697896,94698009,94715210,94715419 |
| teRNA_38017.9 | - | Intergenic | Non-coding | Non-coding | chrX(-):94570126,94570146,94697896,94698009,94715210,94715419 |
| teRNA_38017.10 | - | Intergenic | Non-coding | Non-coding | chrX(-):94676046,94676066,94697896,94698009,94715210,94715419 |
1
2
GTEx
The proportion of samples in which the TE-initiated transcript was expressed across 46 body sites in the Genotype-Tissue Expression (GTEx) project.
TCGA
The proportion of samples in which the TE-initiated transcript was expressed across 33 cancer types from The Cancer Genome Atlas (TCGA).
GTEx
The expression of TE-initiated transcript across 46 body sites from The Genotype-Tissue Expression (GTEx) project.
